title: Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer.
abstract: The miR-302 family is one of the main groups of microRNAs, which are highly expressed in embryonic stem cells (ESCs). Previous reports have indicated that miR-302 can reduce the proliferation rate of some cancer cells while compromising on their oncogenic potential at the same time without having the same effect on normal somatic cells. In this study we aimed to further investigate the role of the miR-302 cluster in multiple cancer signaling pathways using A-375 melanoma and HT-29 colorectal cancer cells. Our results indicate that the miR-302 cluster has the potential to modulate oncogenic properties of cancer cells through inhibition of proliferation, angiogenesis and invasion, and through reversal of the epithelial-to-mesenchymal transition (EMT) in these cells. We showed for the first time that overexpression of miR-302 cluster sensitized A-375 and HT-29 cells to hypoxia and also to the selective BRAF inhibitor vemurafenib. MiR-302 is a pleiotropically acting miRNA family which may have significant implications in controlling cancer progression and invasion. It acts through a reprogramming process, which has a global effect on a multitude of cellular pathways and events. We propose that reprogramming of cancer cells by epigenetic factors, especially miRNAs might provide an efficient tool for controlling cancer and especially for those with more invasive nature.
authors.affiliation: Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
authors.forename: Hamid
authors.initials: H
authors.lastname: Maadi
authors.affiliation: Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
authors.forename: Abdolvahab
authors.initials: A
authors.lastname: Moshtaghian
authors.affiliation: Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
authors.forename: Masoumeh Fakhr
authors.initials: MF
authors.lastname: Taha
authors.affiliation: Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
authors.forename: Seyed Javad
authors.initials: SJ
authors.lastname: Mowla
authors.affiliation: Department of Genetics, Faculty of Science, Shahid Chamran University, Ahwaz, Iran.
authors.forename: Asiye
authors.initials: A
authors.lastname: Kazeroonian
authors.affiliation: The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia.
authors.forename: Nikolas K
authors.initials: NK
authors.lastname: Haass
authors.affiliation: Department of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran. Electronic address: arashj@nigeb.ac.ir.
authors.forename: Arash
authors.initials: A
authors.lastname: Javeri
mesh_terms: D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D002448:Cell Adhesion / Q000187:drug effects / Q000235:genetics; D003110:Colonic Neoplasms / Q000473:pathology*; D053595:Embryonic Stem Cells / Q000187:drug effects / Q000378:metabolism; D019073:HT29 Cells; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000235:genetics; D008545:Melanoma / Q000473:pathology*; D035683:MicroRNAs / Q000235:genetics*; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic / Q000235:genetics; D013449:Sulfonamides / Q000494:pharmacology; D000072258:Tumor Hypoxia / Q000187:drug effects / Q000235:genetics; D015854:Up-Regulation / Q000187:drug effects / Q000235:genetics; D000077484:Vemurafenib
chemical_list: D007211:Indoles; C532169:MIRN302A microRNA, human; D035683:MicroRNAs; D013449:Sulfonamides; D000077484:Vemurafenib
keywords: Cancer; Colon; Reprogramming; Skin; miRNA